Trial
NCT05048134
A Phase I Study of HRS2300 or Combined With SHR-1316 or SHR-1701 or Trametinib or Almonertinib in Patients With Advanced Malignancies
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Collaborators
—
Condition
Advanced Malignancies
Intervention
HRS2300
Why stopped
Sponsor R\&D strategy adjustment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-09-19